Norges Bank’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-699,170
Closed -$4.85M 2081
2023
Q1
$4.85M Sell
699,170
-80,631
-10% -$742K ﹤0.01% 1766
2022
Q4
$8.02M Buy
779,801
+57,258
+8% +$1.01M ﹤0.01% 1633
2022
Q3
$13.2M Buy
722,543
+63,568
+10% +$2.75M ﹤0.01% 1424
2022
Q2
$33.9M Buy
658,975
+39,606
+6% +$2.05M 0.01% 975
2022
Q1
$45.6M Buy
619,369
+2,213
+0.4% +$197K 0.01% 942
2021
Q4
$88.3M Sell
617,156
-17,353
-3% -$2.98M 0.02% 666
2021
Q3
$132M Buy
634,509
+35,155
+6% +$7.75M 0.03% 526
2021
Q2
$127M Buy
599,354
+48,075
+9% +$8.81M 0.03% 554
2021
Q1
$100M Sell
551,279
-7,413
-1% -$1.48M 0.02% 640
2020
Q4
$62.3M Buy
558,692
+39,132
+8% +$4.16M 0.01% 827
2020
Q3
$56.3M Buy
+519,560
New +$63.3M 0.02% 779
2017
Q2
Sell
-40,589
Closed -$1.04M 2149
2017
Q1
$1.04M Sell
40,589
-90,362
-69% -$2.48M ﹤0.01% 2055
2016
Q4
$3.3M Hold
130,951
﹤0.01% 1922
2016
Q3
$5.2M Buy
130,951
+18,546
+16% +$2.39M ﹤0.01% 1864
2016
Q2
$16.3M Hold
112,405
0.01% 1329
2016
Q1
$11.6M Hold
112,405
0.01% 1484
2015
Q4
$18.9M Hold
112,405
0.01% 1197
2015
Q3
$15.9M Hold
112,405
0.01% 1265
2015
Q2
$25M Buy
112,405
+12,500
+13% +$2.2M 0.01% 1057
2015
Q1
$16.5M Buy
+99,905
New +$16.2M 0.01% 1316

Other funds holding NVAX

Norges Bank's NVAX Position: Q2 2023 in Review

Norges Bank sold out of Novavax (NVAX) in Q2 2023, closing a stake of 699,170 shares — an estimated $4.85M sold.

Norges Bank first reported a position in NVAX in Q1 2015 and held it in 20 quarters. The position peaked at $132M in Q3 2021. 215 funds tracked by Wall St. Rank hold NVAX as of Q2 2023.

  • Norges Bank reported no remaining Novavax position as of Q2 2023 after selling out during the quarter.
  • Norges Bank sold 699,170 Novavax shares in Q2 2023, an estimated $4.85M.
  • Norges Bank first reported a position in Novavax in Q1 2015 and held it in 20 quarters.
  • Norges Bank's Novavax position peaked at $132M in Q3 2021.
  • 215 funds tracked by Wall St. Rank held Novavax as of Q2 2023.

Based on Norges Bank's 13F filing for Q2 2023, filed 14 Aug 2023.